Monopar presents Phase 2 data showing ALXN1840 benefits for Wilson disease

June 1, 2026 7:00 AM

Monopar Therapeutics Inc. (NASDAQ: MNPR) presented Phase 2 trial data for ALXN1840 at the European Association for the Study of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found